Intravenous Furosemide in Acute Kidney Injury
Primary Recommendation
Do not use IV furosemide to prevent or treat AKI itself; use it only for managing volume overload when present. 1
The 2012 KDIGO guidelines explicitly state that diuretics should not be used to prevent AKI (Class 1B recommendation) and should not be used to treat AKI except in the management of volume overload (Class 2C recommendation). 1 This represents the highest-level guideline evidence available and must frame all furosemide use in the AKI setting.
When to Administer IV Furosemide in AKI
Indication: Volume Overload Only
- Administer IV furosemide only when clinical signs of volume overload are present: pulmonary edema (bilateral crackles), peripheral edema ≥2+, elevated jugular venous pressure, or ascites. 1, 2
- Systolic blood pressure must be ≥90 mmHg; hypotension predicts poor diuretic response and furosemide should be withheld until hemodynamic support is provided. 1, 2, 3
- Severe hyponatremia (Na⁺ <130 mEq/L) or metabolic acidosis should be corrected first, as these conditions markedly reduce diuretic efficacy. 1, 2, 3
Contraindications in AKI
- Do not give furosemide to prevent AKI progression or accelerate renal recovery—high-dose furosemide in established AKI requiring dialysis does not improve survival, reduce dialysis sessions, or shorten time on dialysis. 4
- Do not use furosemide as a therapeutic agent for AKI; it may increase urine output but does not alter mortality or renal recovery rates. 4
Dosing Strategy
Initial IV Bolus
- Diuretic-naïve patients: give 20–40 mg IV over 1–2 minutes. 2, 3, 5
- Patients on chronic oral loop diuretics: give at least 2× the total daily oral dose IV (e.g., 40 mg PO daily → ≥80 mg IV). 3, 6, 5
- Severe volume overload: may start with 40–120 mg IV bolus in the acute setting. 3
Dose Escalation Limits
- First 6 hours: total furosemide <100 mg. 2, 3, 6
- First 24 hours: total furosemide <240 mg. 2, 3, 6
- Maximum daily dose: 600 mg (up to 620 mg in continuous infusion protocols). 3, 6, 5
Continuous Infusion (Alternative to Bolus)
- Loading dose: 40 mg IV bolus. 3, 6
- Infusion rate: start at 5–20 mg/hour, titrate by doubling every 1–2 hours until urine output >0.5 mL/kg/hour, maximum 40 mg/hour. 3, 6, 7
- Continuous infusion is at least as safe and effective as repeated boluses for the same total dose. 3, 7
Monitoring Parameters
Immediate (Every 1–4 Hours)
- Hourly urine output via urinary catheter to assess diuretic response. 2, 3, 6
- Blood pressure every 1–4 hours to detect hypotension. 3, 6
- Clinical congestion assessment: jugular venous pressure, lung crackles, peripheral edema. 3, 6
Daily
- Body weight at the same time each day. 3, 6
- Strict intake-output balance. 3, 6
- Serum electrolytes (K⁺, Na⁺, Mg²⁺). 3, 6
- Renal function (creatinine, BUN). 3, 6
Predictors of Diuretic Response
- Spot urine sodium ≥50–70 mEq/L measured 2 hours after the first dose predicts adequate natriuresis. 3
- Measured creatinine clearance is the only reliable predictor of urine output response to furosemide in AKI; AKI staging and volume markers (CVP, BNP, fractional sodium excretion) do not predict response. 8
Management of Inadequate Diuresis (Sequential Nephron Blockade)
Step 1: Escalate Loop Diuretic
- Double the IV furosemide dose every 2–3 days until satisfactory decongestion, not exceeding 600 mg/day. 3, 6
Step 2: Add Thiazide-Type Diuretic
- Metolazone 2.5–5 mg PO once or twice daily. 3, 6
- Chlorothiazide 500–1,000 mg IV once or twice daily. 3, 6
- Hydrochlorothiazide 25 mg PO as an alternative. 2, 3
Step 3: Add Aldosterone Antagonist
- Spironolactone or eplerenone 25–50 mg PO daily for synergistic natriuresis and to mitigate hypokalemia. 2, 3, 6
- Low-dose combination therapy (loop + thiazide + aldosterone antagonist) is more effective and produces fewer adverse effects than high-dose loop monotherapy. 3, 6
Renal Function Considerations in AKI
Expected Creatinine Changes
- A creatinine rise <30% from baseline during effective decongestion is common and does not predict worse outcomes; continue furosemide. 3, 6
- A creatinine rise >30% with persistent congestion signals worsening heart failure or AKI, not volume depletion—intensify therapy rather than stop diuretics. 3, 6
Pharmacokinetic/Pharmacodynamic Alterations
- Both altered pharmacokinetics (reduced furosemide excretion) and reduced pharmacodynamics (tubular resistance) occur when creatinine clearance <40 mL/min. 8
- When creatinine clearance <20 mL/min or urine output <500 mL/12 hours, pharmacodynamic limitations dominate and furosemide response becomes unpredictable. 7
Furosemide Does Not Improve AKI Outcomes
- High-dose furosemide (25 mg/kg/day IV or 35 mg/kg/day PO) in established AKI requiring dialysis does not improve survival or renal recovery, though it shortens time to achieve 2 L/day diuresis (5.7 vs 7.8 days, p=0.004). 4
- Furosemide helps maintain urine output but has no impact on dialysis requirements or mortality. 4
Safety and Adverse Effects
Electrolyte Disturbances
- Hypokalemia is the most common adverse effect; replace aggressively to maintain K⁺ ≥4.0 mEq/L. 3, 6
- Hyponatremia may worsen with high-dose furosemide; monitor closely. 3, 6
- Hypomagnesemia should be corrected, as low Mg²⁺ impairs potassium repletion and increases diuretic resistance. 3, 6
Ototoxicity Prevention
- Do not exceed 6 mg/kg/day for more than 1 week. 3, 6
- Infuse IV furosemide over 5–30 minutes (not faster than 4 mg/min) to reduce hearing loss risk. 3, 5
Drug Interactions
- Avoid NSAIDs—they blunt diuretic response and worsen renal function. 3, 6
- Continue ACE inhibitors/ARBs and beta-blockers unless hemodynamic instability develops. 3, 6
Common Pitfalls
- Do not stop furosemide for mild creatinine elevation (<30% rise) during effective decongestion—this is expected and benign. 3, 6
- Do not assume hypovolemia in AKI patients with hyponatremia—they are typically volume-overloaded and require intensified diuresis, not fluid resuscitation. 3
- Do not use furosemide to "protect" or "treat" the kidneys—it only manages volume overload and does not alter AKI progression or outcomes. 1, 4
- Do not rely on AKI stage, CVP, BNP, or fractional sodium excretion to predict furosemide response—measured creatinine clearance is the only reliable predictor. 8
Furosemide Stress Test (FST) for AKI Prognosis
Emerging Role (Not Standard Practice)
- FST (standardized furosemide dose followed by 2-hour urine output measurement) predicts AKI progression and RRT need better than static biomarkers. 9, 10, 11
- FST is a research tool, not a guideline-recommended intervention; it assesses tubular function and functional reserve but does not change management in routine practice. 9
- Furosemide responsiveness (urine output ÷ furosemide dose) inversely correlates with AKI progression risk in cardiac surgery and sepsis-associated AKI. 10, 11